............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
Concert Pharmaceuticals Announces
Pricing of Initial Public Offering
LEXINGTON, Mass.-- Feb 13, 2014 --Concert Pharmaceuticals, Inc. today
announced the pricing of its initial public offering of 6,000,000 shares
of its common stock at a public offering price of $14.00 per share,
before underwriting discounts. In addition, Concert has granted the
underwriters a 30-day option to purchase up to an additional 900,000
shares of common stock at the same price to cover over-allotments. The
shares are scheduled to begin trading on the NASDAQ Global Market on
February 13, 2014 under the ticker symbol “CNCE.”
The offering is expected to close on February 19, 2014, subject to
customary closing conditions.
UBS Investment Bank and Wells Fargo Securities are acting as joint
book-running managers for the offering. JMP Securities is acting as lead
manager and Roth Capital Partners is acting as co-manager for the
offering.
A registration statement relating to the securities being sold in this
offering has been filed with and declared effective by the Securities
and Exchange Commission. The offering is being made only by means of a
prospectus, copies of which may be obtained from UBS Investment Bank,
Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171,
or by phone at 1-888-827-7275; or Wells Fargo Securities, Attention:
Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152,
or by email at cmclientsupport@wellsfargo.com, or by phone at
1-800-326-5897.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such state or jurisdiction.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE Platform® (deuterated chemical entity
platform) to create novel small molecule drugs. This approach starts
with approved drugs, advanced clinical candidates or previously studied
compounds that have the potential to be improved with deuterium
substitution to enhance clinical safety, tolerability and efficacy. The
company is developing a broad pipeline targeting CNS disorders, renal
disease, inflammation and cancer.
Contacts
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
Vice President, Corporate Communications and Investor Relations
ir @concertpharma.com |